Early Life and Medical Education
Charles David Kelman was born on January 16, 1937, in New York City to a family of modest means. Raised in Manhattan, he displayed an early fascination with both physics and biology, pursuits that later converged in his medical career. Kelman attended the Massachusetts Institute of Technology, earning a Bachelor of Science in physics in 1958. His scientific grounding informed a methodical approach to problem‑solving that would become a hallmark of his later work.
After MIT, Kelman enrolled at Harvard Medical School, receiving his M.D. in 1962. He completed an internship in internal medicine at the Boston City Hospital before entering a residency in ophthalmology at the Indiana University School of Medicine (1962‑1966). During this period he also earned a Master of Science in physiology, further integrating basic science with clinical training. Mentors such as Dr. Harold D. Crouch and Dr. William R. Green emphasized rigorous clinical observation, shaping Kelman’s investigative mindset.
Entry Into Ophthalmology and Early Research
Following his residency, Kelman accepted a research fellowship at the National Institutes of Health (NIH), specifically within the National Eye Institute (NEI) in Bethesda, Maryland (1966‑1968). The NIH environment provided access to emerging ultrasonic technology, which, at the time, was primarily employed in industrial cleaning and sonar applications. Kelman hypothesized that high‑frequency ultrasonic energy could be harnessed to fragment cataractous lenses within the eye, eliminating the need for large incisions.
During his NIH tenure he collaborated with engineers and physicists, constructing the first experimental ultrasonic probe. Early laboratory experiments on animal eyes demonstrated that ultrasonic energy could emulsify lens material without damaging surrounding ocular structures. These findings formed the basis for his later clinical application.
Major Work and Career Milestones
In 1968 Kelman joined the faculty of the University of Chicago’s Department of Ophthalmology as an assistant professor. He continued refining his ultrasonic probe, integrating it with a suction system that would later become known as the phacoemulsification hand‑piece. In 1970 he moved to the University of Illinois Hospital and Medical Center (now the University of Illinois at Chicago), where he was appointed chief of the Department of Ophthalmology in 1971.
The landmark moment arrived on February 16, 1972, when Kelman performed the first successful phacoemulsification cataract extraction on a 55‑year‑old patient. The procedure utilized a 2.2‑mm corneal incision, an ultrasonic probe that emulsified the cataract, and aspiration of the resulting fragments, followed by implantation of an intra‑ocular lens (IOL). This breakthrough reduced operative time, minimized postoperative inflammation, and allowed most patients to be discharged the same day.
Kelman’s invention rapidly attracted both enthusiasm and skepticism. He patented the technique (U.S. Patent 4,074,859, 1978) and founded the surgical instrument company Ultrasonics International (later merged into Alcon Laboratories) to manufacture phacoemulsification devices. Over the next decade he published more than 150 peer‑reviewed papers and authored several textbook chapters describing the physics, safety parameters, and clinical outcomes of the method.
Beyond technical development, Kelman was a prolific educator. He established the “Kelman Surgical Training Program,” which sent fellow ophthalmologists to centers worldwide for hands‑on apprenticeship. By the early 1990s, phacoemulsification had become the dominant technique for cataract surgery globally, accounting for over 90 % of procedures in many developed countries.
Specialty, Methods, and Professional Style
Kelman’s specialty was cataract surgery, a subspecialty within ophthalmology that deals with removal of the opaque crystalline lens and restoration of visual acuity. He championed a philosophy of “precision with minimal trauma,” advocating for the smallest possible corneal incision and the use of real‑time intra‑operative monitoring to safeguard endothelial cells and avoid postoperative complications.
Methodologically, Kelman combined experimental physics, rigorous clinical trials, and iterative device engineering. He emphasized outcome data, routinely publishing randomized comparative studies that demonstrated lower rates of postoperative astigmatism, infection, and visual recovery times compared with conventional extracapsular cataract extraction (ECCE). His teaching style was hands‑on and data‑driven; trainees were required to record pre‑ and post‑operative visual acuity, corneal thickness, and endothelial cell counts for every case.
Reception, Awards, and Controversies
Kelman’s phacoemulsification initially faced resistance from surgeons accustomed to larger‑incision techniques. Critics voiced concerns about intra‑ocular damage from ultrasonic energy and the steep learning curve. Nonetheless, as large‑scale outcome studies accumulated, the method gained universal acceptance. By the late 1980s, the American Academy of Ophthalmology (AAO) endorsed phacoemulsification as the standard of care for age‑related cataracts.
Kelman’s contributions earned numerous honors. He received the Gonin Medal from the International Society of Cataract and Refractive Surgery in 1997, one of the highest recognitions in ophthalmology. In 1999 he was awarded the National Medal of Technology and Innovation by President Bill Clinton, acknowledging the profound public‑health impact of his invention. Posthumously, Kelman was inducted into the National Inventors Hall of Fame (2005) and the International Hall of Fame for Eye Surgeons.
Controversies surrounding Kelman were limited and largely technical. Early debates over the cost of phacoemulsification equipment versus traditional surgical sets were resolved as economies of scale reduced prices. No credible allegations of scientific misconduct, malpractice, or ethical violations have been documented in reputable sources.
Legacy and Medical Impact
Charles Kelman’s invention transformed cataract surgery from an inpatient procedure with large incisions to a largely outpatient, micro‑incisional operation performed in a modest clinical setting. Today, phacoemulsification is regarded as the “gold standard,” with an estimated 20 million cataract surgeries performed annually worldwide, the majority using his technique.
Beyond the numbers, Kelman’s legacy includes the establishment of modern ophthalmic device development pathways, the integration of engineering and medicine, and a culture of evidence‑based surgical innovation. His training programs continue to influence generations of ophthalmic surgeons, and his patents laid groundwork for subsequent advances such as femtosecond laser‑assisted cataract surgery.
Kelman’s work also had broader public‑health implications. By making cataract surgery safer, faster, and less costly, vision impairment due to cataract has dramatically declined in high‑income nations, contributing to improved quality of life for elderly populations and reduced socioeconomic burden.
